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Addressing the mental health needs of
children affected by HIV in Rwanda:
validation of a rapid depression screening
tool for children 7–14 years old
Agnes Binagwaho1,2,3, Eric Remera1,4, Alice Uwase Bayingana1* , Darius Gishoma5, Kirstin Woody Scott6,
Madeline Goosman1, Eliza Campbell7, Mawuena Agbonyitor8, Yvonne Kayiteshonga4 and Sabin Nsanzimana1,4

Abstract
Background: Depression in children presents a significant health burden to society and often co-exists with
chronic illnesses, such as human immunodeficiency virus (HIV). Research has demonstrated that 10–37% of children
and adolescents living with HIV also suffer from depression. Low-and-middle income countries (LMICs) shoulder a
disproportionate burden of HIV among other health challenges, but reliable estimates of co-morbid depression are
lacking in these settings. Prior studies in Rwanda, a LMIC of 12 million people in East Africa, found that 25% of
children living with HIV met criteria for depression. Though depression may negatively affect adherence to HIV
treatment among children and adolescents, most LMICs fail to routinely screen children for mental health problems
due to a shortage of trained health care providers. While some screening tools exist, they can be costly to
implement in resource-constrained settings and are often lacking a contextual appropriateness.
Methods: Relying on international guidelines for diagnosing depression, Rwandan health experts developed a
freely available, open-access Child Depression Screening Tool (CDST). To validate this tool in Rwanda, a sample of
296 children with a known diagnosis of HIV between ages 7–14 years were recruited as study participants. In
addition to completing the CDST, all participants were evaluated by a mental health professional using a structured
clinical interview. The validity of the CDST was assessed in terms of sensitivity, specificity, and a receiver operating
characteristic (ROC) curve.
Results: This analysis found that depression continues to be a co-morbid condition among children living with HIV
in Rwanda. For identifying these at-risk children, the CDST had a sensitivity of 88.1% and specificity of 96.5% in
identifying risk for depression among children living with HIV at a cutoff score of 6 points. This corresponded with
an area under the ROC curve of 92.3%.
(Continued on next page)
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Conclusions: This study provides evidence that the CDST is a valid tool for screening depression among children
affected by HIV in a resource-constrained setting. As an open-access and freely available tool in LMICs, the CDST
can allow any health practitioner to identify children at risk of depression and refer them in a timely manner to
more specialized mental health services. Future work can show if and how this tool has the potential to be useful
in screening depression in children suffering from other chronic illnesses.
Keywords: Depression scale, Validation, Child mental health, HIV/AIDS, Rwanda

Background
Depression is a serious co-morbid condition associated
with a variety of chronic medical illnesses, often limiting
a patient’s ability to achieve optimal outcomes [1, 2]. According to the World Health Organization (WHO), the
prevalence of depression is estimated to be 4.4% [3]. The
burden is even higher among individuals suffering from
human immunodeficiency virus (HIV), ranging from 10
to 37% [4, 5]. Children with HIV are uniquely vulnerable
to depression relative to their counterparts [6]. This
added burden of depression to that of HIV is concerning
as it negatively impacts quality of life and adherence to
HIV treatment [4].
Though challenges exist, there is effective treatment
for depression in patients with HIV [3, 4]. However,
low-and-middle income countries (LMICs) face chronic
shortages of mental health providers; fewer than 25% of
affected individuals ever access mental health treatment
[7, 8]. In response, the WHO launched the mental
health Gap Action Programme (mhGAP) in 2008,
https://apps.who.int/iris/handle/10665/43809, to support
initiatives that would aid in more rapid screening, diagnosis, and treatment of mental illness, including depression, in LMICs [9, 10]. Rwanda, a country of 12 million
people in Sub-Saharan Africa, embraced the principles
of mhGAP but barriers persist in meeting its ideals of
providing adequate, timely mental health care to all in
need. For instance, a 2018 national survey showed that
86% of Rwandans who met criteria for a mental disorder
did not seek care [9]. When studying the prevalence of
depression among children affected by HIV [11, 12], it
was found that 25% of children living with HIV in
Rwanda also met criteria for depression [11].
The burden of depression among children living with
HIV, especially in LMICs where access to mental health
services is limited, underscores the need for increased
attention to the psychological needs and well-being of
this vulnerable group. In response to these findings,
Rwanda’s Ministry of Health recommended routine
screening for depression among children living with
HIV. Though well-intentioned, there were no easily accessible tools to Rwandan clinicians or the few mental
health providers that existed in the country. As such,
screening for depression among children rarely occurred

[13]. Therefore, the purpose of this study is to describe
both the development of Rwanda’s Children Depression
Screening Tool (CDST) as well as the process of validating this tool by comparing results with a Rwandan national survey. The CDST was designed to be a practical
resource for Rwandan clinicians to rapidly and effectively screen children living with HIV in the country.

Methods
Creation of the CDST

Though validated screening tools have been helpful with
optimizing health outcomes in depression [14, 15], there
have been relatively few efforts to develop and validate
screening tools for depression among the pediatric
population with HIV in LMICs. A literature review of
the existing validated depression assessment tools available around the world, and specifically in Rwanda, both
in terms of their content, availability, ease of use, predictive validity, and cultural sensitivity, was conducted in
2015, finding that the tools available at the time were either insufficient or unaffordable in the Rwandan context.
There were no other rapid assessment tools for depression previously validated in Rwanda other than the
Children’s Depression Inventory (CDI), which is a tool
available only by cost for each single use. Given the prohibitive cost to expand this nationally in a LMIC, this
motivated the development of a new freely-accessible alternative that would allow Rwanda to screen children for
depression nationally.
With the support of experienced Rwandan psychologists, psychiatrists, and pediatricians, the CDST was developed and copyrighted as a free, open source tool. The
development of the CDST was based on a variety of
existing international tools for diagnosing depression, including the WHO and Diagnostic Statistical Manual of
Mental Disorders, fourth edition (DSM-IV). In addition,
the CDST was designed to be validated against a national standard interview guide in Kinyarwanda, which
was created based on WHO norms to standardize interviews for diagnosing depression among children in the
country. For instance, the Rwandan expert team also
considered previous studies on local concepts of
depression-like problems in Rwandan children and adolescents affected by HIV/AIDS. Majority of expression
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used such as agahinda kenshi (persistent sorrow) and
kwiheba (severe hopelessness) were found to correlate
with some of the DSM-IV criteria [16, 17]. These
culture-specific expressions serve as examples for how
the CDST took into account the Rwandan context when
designing this screening tool. The CDST was designed
to be a practical, usable tool for non-mental health specialists such as nurses and general practitioners working
in primary health care settings.
The CDST is composed of 11 questions relating to the
themes of mood, interest in leisure, hope of living, fatigue, psychomotor activity, sleep, appetite, concentration, interpersonal relationships, suicidal thoughts or
suicide attempts and the feeling of guilt. Each question
had a four point answer scale (0 = absence of symptoms,
1 = symptom sometimes present, 2 = symptom frequently
present, 3 = symptom always present) to assess the
mood, interest in leisure, hope of living, fatigue, psychomotor activity, sleep, appetite, concentration, interpersonal relationships, suicidal thoughts or suicide attempts
and the feelings of guilt. The CDST was translated by
Rwandan psychologists and psychiatrists into Kinyarwanda, ensuring that local culture was taken in account,
and was subsequently back translated to English by a different team of psychologists and psychiatrists. The tool
was beta tested in two randomly selected sites (one
urban and one rural) to identify ambiguities and assure
question clarity. Based on the feedback received from
users and respondents, the tool was updated into a final
version used for data collection.
Validation of the CDST
Study design and sampling

The CDST validation study was carried out from August
1, 2019 to November 5, 2019. The population of interest
were children living with HIV in Rwanda. The study was
limited to children between the ages of 7 to 14 as it required that children have a known positive HIV status
and ability to participate in the depression screening.
According to the national HIV program, there were approximately 5000 children [18] aged 7 to 14 years living
with HIV on antiretroviral therapy (ART) in Rwanda; it
was expected that approximately 25% would meet criteria for depression. This population along with the tool
parameters (7% absolute precision, design effect of 1.2,
and adjusting for the non-response rate and the expected specificity of 90%), a final sample size of 283 was
needed for this analysis. According to guidelines on HIV
disclosure among children in Rwanda, it is recommended to provide complete disclosure of HIV/AIDS
status before 14 years. Previous study indicated that children aged 7 and above in Rwanda were more likely to be
aware of their HIV status than their younger counterparts [19]. In order to select the study sites and

Page 3 of 8

participants, a list of health facilities per province offering HIV care and treatment services to children was extracted from Rwanda’s Ministry of Health Management
Information System. To assure adequate representation
from rural areas, two urban health facilities and three
rural health facilities were randomly selected as study
sites from each of Rwanda’s five provinces. In each of
the 25 selected facilities, a study assistant randomly selected 12 participants who would undergo both the
CDST screening tool as well as a diagnostic interview by
mental health professionals, the latter of which was considered the gold standard for diagnosing depression.
Standardized clinical interview for DSM-IV (SCID)

All participants who underwent the CDST screening
tool were also interviewed by one of five mental health
professionals. These professionals had 5 to 20 years of
clinical experience and had a systematic interview tool
to assess participants as to whether or not they met criteria for Major Depressive Disorders from the DSM-IV.
The Structured Clinical Interview for DSM- IV (SCID) is
widely considered the gold standard in both clinical
practice and research [20]. The procedure has been validated in East African settings [21] and the Kinyarwanda
Structured Clinical Interview for Depression have been
widely used in different studies in the Rwandan context
[11, 22]. Children and their guardians were asked to participate in the study on a voluntary basis and understood
that they could end their participation at any moment
with no consequences to their right to access health services. All children suspected to have mental health problems were referred for appropriate care and follow up
regardless of their participation in the study.
Study variables

Beyond the data captured from the CDST and interview process, the following participant demographics,
socioeconomic, and clinical status variables were captured for the purposes of the study, including: age,
gender, education, survivorship of parents, person living with the child, the person who disclosed the HIV
status to the child, time on ART treatment, and recent HIV viral load.
Statistical analysis

The results of the CDST were compared to those of the
SCID gold standard interview (as conducted by the
trained senior mental health professionals). This permitted for the calculation of the sensitivity, specificity,
positive predictive value, and negative predictive value
estimates for the CDST. For every sampled child, a
CDST score was calculated, then at every cut-off score, a
Receiver Operating Characteristic (ROC) analysis was
performed to determine the recommended cut-off that
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would make this an appropriate screening tool for depression among Rwanda’s population.

Results
Validation study participants and demographics

The CDST was finalized in May 2019. A total of 296
children (49% male and 51% female) participated in the
study with ages ranging from 7 to 14 years (mean: 12,
SD: 1.9). The majority of children had both parents alive
(93.6%) and were living with their parents (86.1%), while
13.9% lived with their siblings, relatives or another
guardian. The majority (94.2%) attended primary school
and 5.8% attended secondary school. In terms of HIV
disclosure prior to the study, 53.3% of respondents
found out their HIV status from their parents/guardians
while the remaining 42.1% had their status disclosed by
the assistance of a health care provider with or without
parental involvement. All children were receiving ART,
with the majority of children (80%) showing a viral load
below the threshold of < 1000 RNA copies/ml. Nonsuppressed HIV viral load was found in 19% of the participants. With regards to geography, children living in
the Western province had higher rates of depression
relative to those in other areas. [Table 1].
Prevalence of depression using clinical interview/gold
standard

According to the SCID gold standard process, a total of
14.2% (95% CI: 9.6, 20.4) of children were found to have
depression. Depression was highest among adolescents
aged 13–14 years relative to younger children (p < 0.05).
Further the province of residence was associated with
depression, with a higher prevalence in the western
province (p < 0.05). [Table 1].
Identifying depression using the CDST tool

The CDST scores were compared to the results of the
clinical interviews to determine sensitivity (proportion of
children who have depression according to clinical interview and who are correctly identified by CDST) and specificity (proportion of children without depression and
who have been correctly identified as non-depressed by
the CDST). The optimal cut-off point for an accurate
determination of the risk of depression (a positive
screen) using the CDST tool was determined. A threshold score of 4 was found to be associated with 95.2% of
children with depression diagnosis, while a 10 cut-off
score was associated only with 40.5% of the subjects with
depression. Analyzing the CDST at different scores, the
specificity was 86.6% at the cut-off point of 4 and 99.6%
at the cut-off point of 10. The cut-off points of 5 to 6
appeared to provide the optimal levels of sensitivity and
specificity compared to the rest of the scores. [Table 2].
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Finally, a ROC analysis was completed to determine
the global functioning of the scale as well as overall accuracy of the CDST tool in identifying depression risk.
The cut-off point of 6 achieved the greatest area under
the curve (92.3%) with a marked increase in specificity.
[Fig. 1].

Discussion
This article summarizes the creation of a newly developed, freely-accessible tool in Rwanda for screening depression among children suffering from HIV, how it was
adapted to the Rwandan context, and how the CDST
tool was validated.
This analysis found that 14% of children living with
HIV in Rwanda screened positive for depressive symptoms. Though not a majority, this suggests the importance of having readily accessible tools in Rwanda to
identify this uniquely at-risk population so that both
their HIV burden and mental health suffering can be
minimized. Similar to prior work, this study showed that
children living with HIV ages 7–14 years in Rwanda had
the highest prevalence of depression in the western
province [11]. Several factors may contribute to this pattern including, but not limited to, geographical accessibility; the region is mountainous with limited access to
existing primary health facility network [23], socioeconomic factors; the highest rates of extreme poverty and
malnutrition can be found in the south and west of the
country [24], and other historical reasons such as the
traumatic impact of the genocide [25].
Compared to prior studies that utilized the CDI tool,
this study found a lower prevalence of depression among
this vulnerable population (14% with the CDST versus
25% with the CDI) [11]. Though lower, this rate still falls
within the range of prior studies suggesting that depression rates among children with HIV varies from 10 to
37% [4]. This discrepancy between the tools may also be
contextual; the CDI tool was created for children in the
USA, while the CDST was adapted to the Rwandan local
setting, which may alter its screening accuracy.
Results from this study indicated that the presence of
depressive symptoms was also associated with being female and an adolescent (ages 13–14). Studies conducted
in other settings have shown no differences in depression rates by sex in childhood and prepubescence; however, a gap appears to emerge between the ages of 11
and 15 as girls become approximately twice as likely as
boys to experience depression [26–29]. This gender gap
appears to persist through adulthood where depression
affects women more than men [26–30]. A variety of
deeply rooted social factors may contribute to the
gender-linked vulnerability to depressive symptoms not
only in Rwanda but also in other contexts, which are
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Table 1 Demographic Characteristics and prevalence of depression
N

%

296

Prevalence of depression
%

95% CI

14.2

[9.6,20.4]

Province
East

60

20.3

11.7

[4.5,27.1]

West

70

23.6

24.3

[17.0,33.4]

City of Kigali

57

19.3

15.8

[6.3,34.2]

North

53

17.9

3.8

[1.2,11.1]

South

56

18.9

12.5

[5.4,26.4]

9-Jul

46

15.5

6.5

[2.2,17.9]

12-Oct

114

38.5

9.6

[5.1,17.5]

13–14

136

45.9

20.6

[13.8,29.6]

Male

145

49

11

[6.5,18.0]

Female

151

51

17.2

[11.3,25.3]

Urban

146

49.3

13.7

[7.5,23.8]

Rural

150

50.7

14.7

[9.0,23.1]

Primary

275

94.2

14.2

[9.8,20.1]

Secondary

17

5.8

17.6

[4.9,47.0]

Age of the child (years)

Sex of the child

Residence facility

Current education level

Parents are alive?
Both Alive

277

93.6

14.1

[9.5,20.4]

One Alive

19

6.4

15.8

[3.8,46.8]

Parents

255

86.1

13.3

[8.2,20.9]

Siblings/relatives/Guardian

41

13.9

19.5

[10.8,32.7]

Below 24 months

27

9.1

14.8

[6.8,29.4]

25–60 months

61

20.6

13.1

[6.1,25.9]

Person living with the child when out of school

Time on ART

61–120 months

139

47

12.9

[8.0,20.2]

121+ months

69

23.3

17.4

[7.8,34.3]

152

53.3

13.8

[9.1,20.3]

Who disclosed the HIV Status?
Parents/ Guardian
Parent with Health Care Providers

120

42.1

15.8

[9.3,25.8]

Health Care provider

13

4.6

7.7

[0.9,44.4]

No

50

19.2

16

[7.7,30.3]

Yes

211

80.8

12.3

[8.3,18.0]

Recent viral load suppressed (< 1000 copies)

explored elsewhere and merit further investigation for
addressing.
Prior studies have shown higher rates of depression
and behavioral health challenges among adolescent boys
and girls with perinatally acquired HIV, which are

associated with decreased medication adherence and increased transmission risk [30, 31]. This may be partly explained by the transition to puberty, adolescent
difficulties, parental-child relationship, and circumstances surrounding HIV-status disclosure. During the
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Table 2 Sensitivity and specificity by depression scale
Scale
Cutoff

Sensitivity

Specificity

Area under the curve
(AUC)

Positive predictive
value

Negative predictive value

Four

95.2%

86.6%

0.909

54.1%

99.1%

Five

92.9%

91.3%

0.921

63.9%

98.7%

Six

88.1%

96.5%

0.923

80.4%

98.0%

Seven

78.6%

98.0%

0.883

86.8%

96.5%

Eight

73.8%

99.2%

0.865

93.9%

95.8%

Nine

57.1%

99.6%

0.784

96.0%

93.4%

Ten

40.5%

99.6%

0.700

94.4%

91.0%

recruitment phase of this study, it was observed that disclosure of the diagnosis of HIV to children remained a
challenge for parents and healthcare providers. According to national guidelines, HIV positive status should be
carefully disclosed to affected individuals starting by age
7, however, more than half of children aged 7–9 considered for recruitment were unaware of their HIV status
and were thus excluded in this study. Children had
learned of their HIV status during the pre-adolescence
or adolescence period; this may have led to added emotional distress among those aged 13–15.
The results of this study indicated that the CDST was
found to be feasible tool to implement in Rwanda and
that it was comparable to the gold standard SCID. When
designing a screening tool, it is important to optimize
the benefit of not missing any affected children while
also not burdening the health system (i.e. using a tool
with a high false-positive rate) [32]. This analysis showed
the process for identifying an optimal cut-off score for
the CDST (6 points). As such, this study suggests that

Fig. 1 Receiver Operating Characteristics (ROC) Curve of CDST Tool

the CDST serves as a practical, quality screening tool for
identifying children with HIV at risk for depression and
thus more timely referrals to mental health specialists.
Further, using this score, this sets a limit on the falsepositive rate in order to conserve resources for the few
available mental health professionals in Rwanda. This
will help to improve access to appropriate mental health
prevention, treatment, and supportive services for children in Rwanda at risk of suffering from depression.
Limitations

Though the CDST offers a unique, context-specific tool
for screening depression, there are important limitations
to this study. First, this is limited to a single cohort
within a single country, therefore the generalizability to
other LMIC settings is unclear. Secondly, since the
CDST was tested and validated only among children living with HIV among a particular age group [7 to 14], it
is not possible to confirm the validity of it beyond this
cohort. Nonetheless, given the importance to Rwanda
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for identifying children at risk of depression, the intent
of the CDST is to be available for all children across all
chronic diseases. This will require further efforts to expand the validation population for the tool. Additional
next steps include adopting the tool in the Rwandan national program and continuously monitor its benefits in
improving mental health outcomes. Further, the CDST
tool is freely available for other LMICs to adapt and use,
thereby trying to address the important financial barriers
that previously hindered these resource-limited settings
from national screening efforts among this vulnerable
population.

Conclusion
Currently, the majority of children living with HIV in
LMICs are not systematically screened for depressive
symptoms. These barriers make it difficult for children
in these settings to receive timely mental health care and
treatment, which has a negative impact on their overall
long-term health outcomes. This study shows how a
newly-developed, freely-accessible screening tool created
in a LMIC setting was validated for accurately screening
children living with HIV for depression. This tool was
designed with the intent that it can be used by general
practitioners, nurses, and midwives in their clinical practice to improve assessment, referral and treatment of depression among children and adolescents living with
HIV to the limited mental health practitioners who live
in LMIC settings. Implementing this valid, freely available assessment tool has the potential to strengthen the
mental health referral process, creating a path to the development of an effective child mental health strategy in
Rwanda and beyond.
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